Lapatinibe: uso em mulheres com câncer de mama metastático: revisão sistemática
Ano de defesa: | 2015 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | |
Tipo de documento: | Tese |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Estadual Paulista (Unesp)
|
Programa de Pós-Graduação: |
Não Informado pela instituição
|
Departamento: |
Não Informado pela instituição
|
País: |
Não Informado pela instituição
|
Palavras-chave em Português: | |
Link de acesso: | http://hdl.handle.net/11449/143020 http://www.athena.biblioteca.unesp.br/exlibris/bd/cathedra/05-07-2016/000864495.pdf |
Resumo: | Introduction: The five years survival of women with metastatic breast cancer accounts less than 25%. HER2 is an epidermal growth factor; the overexpression of HER2 in the cancer cells decreases survival of these patients Lapatinib is a drug that blocks the intracellular domain of HER2. This blocking could stop or diminish the cell proliferation and improve the survival of these patients. WE performed systematic review and metaanalysis of studies that analyzed the efficacy and safety of lapatinib associated with chemotherapy or hormone therapy for patients with advanced breast cancer that overexpress HER2. Methods: A search of the studies was conducted in MEDLINE, EMBASE, WEB OF SCIENCE, CENTRAL, ICTRP, ClinicalTrials.gov, Cochrane Breast Cancer Group. There were analyzed as the primary endpoint, overall survival (OS), progression-free survival (PFS) and the quality of life, and as secondary endpoints side effects, Results: We identified and assessed 1298 studies. Appling the inclusion criteria were selected five studies. Together these studies included a total of 1127 patients with advanced breast cancer (TNM stage III or IV) with overexpression of HER2. In conclusion it was observed that: for OS lapatinib combined with other drugs decreases the probability of death in 20% (Hazard Ratio 0.80, 95% CI 0.69 to 0.94) p = 0.005. For PFS, lapatinib decreases the probability of tumor progression events or death from any cause in 48% (hazard ratio 0:58, 95% CI 0.67 to 0:50 P < 0,0001. None of the studies analyzed the quality of life. Refers to side effects, patients receiving Lapatinib had more diarrhea (RR 2.5, 95 CI 1.82 to 3.43; P<0.00001; increased risk of cardiac events (RR 1.74, 95% CI 1.02 the 2.99; P<0.04), and higher discontinuation of treatment (RR 4.00, 95% CI 1.44 the 11.17). Conclusion: The use of Lapatinib associated with other drugs decreases the probability of death and increases the likelihood of disease progression free ... |